Compare Abeona Therapeutics Inc (ABEO) vs Deere & Company (DE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Deere & Company — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Deere & Company trades at $597.11 (market cap $162.94B). The key difference: Deere & Company is far larger — about 436.5× Abeona Therapeutics Inc's market cap, and Deere & Company pays a 1.07% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DE | |
|---|---|---|
Market Cap | $373.32M | $162.94B |
Sector | Health | Industrials |
52-Week High | $7.23 | $662.49 |
52-Week Low | $4.17 | $439.11 |
Enterprise Value | $228.22M | $217.76B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Deere & Company (DE) trades at $603.61, down 2.84% on the day, with the stock showing strong technical momentum despite recent volatility. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $6.55 exceeding estimates by 15%. Fundamentals remain solid with 10.33% net margins and 18.51% ROE, though revenue declined to $44.67B in 2025. Analyst consensus points to 39% buy ratings with a $666.08 price target, representing 10% upside potential.
DE presents a mixed outlook with strong operational execution offset by cyclical headwinds in agricultural equipment demand. The precision agriculture platform offers growth potential, but investors face risks from economic sensitivity and margin pressure. Current valuation at 36x P/E appears elevated relative to historical norms, requiring continued earnings growth to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
